Brief: Hyloris Acquires Global Rights To CRD-102 From Baker Institute

Hyloris Pharmaceuticals SA

08/10/2021 06:05

Oct 8 (Reuters) - HYLORIS PHARMACEUTICALS SA  HYL.BR :
    * EXPANDS CARDIOVASCULAR PIPELINE WITH BREAKTHROUGH
EXTENDED-RELEASE MILRINONE CAPSULE IN LATE-STAGE HEART FAILURE
    * PATIENT-FRIENDLY ALTERNATIVE TO CONTINUOUS IV
ADMINISTRATION -
PROVEN SAFETY AND EFFICACY
    * TARGETING ORPHAN, LATE-STAGE HEART FAILURE INDICATION WITH
HIGH
UNMET MEDICAL NEEDS
    * ACQUIRED GLOBAL RIGHTS FROM BAKER HEART AND DIABETES
INSTITUTE
TO CRD-102 (AND RELATED INTELLECTUAL PROPERTY)
    * WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT,
MANUFACTURING,
REGULATORY AFFAIRS, AND COMMERCIALISATION OF CRD-102
    * WILL PAY AN UPFRONT PAYMENT OF $50,000 TO BAKER INSTITUTE
PLUS
SALES-BASED MILESTONE PAYMENTS
    * WILL PAY TO BAKER INSTITUTE TIERED, SINGLE TO DOUBLE DIGIT
NET
PROFIT SHARES IN MARKETS WHERE HYLORIS INTENDS TO
SELF-COMMERCIALISE CRD-102
    * IN MARKETS HYLORIS INTENDS TO SEEK COMMERCIAL
PARTNERSHIPS,
BAKER INSTITUTE IS ELIGIBLE TO RECEIVE TIERED, SINGLE TO DOUBLE
DIGIT NET PROFIT SHARES ON NET SUB-LICENSE INCOME

Source text for Eikon:  ID:nGNE5MtwYq 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))